Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 886-892

  Bhamra, Rupinder ^a   Sa'ad, Aminu ^a   Bolcsak, Lois E ^a   Janoff, Andrew S ^a   Swenson, Christine E ^a  

^a Liposome Company Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE;

AREA UNDER THE CURVE; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030952914     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.886     Document Type: Article

References (25)

1. Anaissie, E. J., M. White, O. Uzun, C. Singer, G. P. Bodey, D. Matzke, N. Azarnia, and G. Lopez-Berestein. 1995. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial, abstr LM21, p. 330. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Barwicz, J., R. Gaereau, A. Audet, A. Morisset, J. Villiard, and I. Gruda. 1991. Inhibition of interaction between lipoproteins and amphotericin B by some delivery systems. Biochem. Biophys. Res. Commun. 181:722-728.
3. Bennett, J. E. 1976. Amphotericin B binding to serum betalipoprotein, p. 107-109. In K. Iwata (ed.), Recent advances in medical and veterinary mycology. University of Tokyo Press, Tokyo, Japan.
4. Block, E. R., J. E. Bennett, L. G. Livoti, W. J. Klein, R. R. MacGregor, and L. Henderson. 1974. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Ann. Intern. Med. 80:613-617.
5. Brajtburg, J., S. Elberg, J. Bolard, G. S. Kobayashi, R. A. Levy, R. E. Ostlund Jr., D. Schlesinger, and G. Medloff. 1984. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:989-997.
6. Clark, J. M., R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615-621.
7. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob. Agents Chemother. 35:2144-2146.
8. Clemons, K. V., and D. A. Stevens. 1992. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30:353-363.
9. Edmonds, L. C., L. Davidson, and J. S. Bertino, Jr. 1989. Solubility and stability of amphotericin B in human serum. Ther. Drug. Monit. 11:323-326.
10. Grasela, D., J. Echevarria, R. Summerill, D. Gonzalez, B. Christoflo, J. Chang, P. Campos, and A. Llanos-Cuentas. 1993. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC®) or Fungizone® (FZ) in adults with mucocutaneous leishmaniasis, abstr. 1439, p. 382. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
12. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. P. Bonner. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
13. Janoff, A. S., W. R. Perkins, S. L. Saletan, and C. E. Swenson. 1993. Amphotericin B Lipid Complex (ABLC®): a molecular rationale for the altenuation of amphotericin B related toxicities. J. Liposome Res. 3:451-471.
14. Kan, V. L., J. E. Bennett, M. A. Amantea, M. C. Smolskis, E. McManus, D. M. Grasela, and J. W. Sherman. 1991. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. 164:418-421.
15. Lee, J., M. Allende, H. Dollenberg, K. Garrett, J. Berenguer, A. Francesconi, T. Sein, C. Lyman, P. Francis, P. Pizzo, T. Walsh. 1992. Reticuloendothelial loading with Amphotericin B lipid complex (ABLC) - a novel pharmacodynamic approach to the treatment of experimental hepatosplenic candidiasis, abstr 172, p. 139. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Moellering, R. C., Jr. 1995. Principles of anti-infective therapy, p. 199-212. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
17. Olsen, S. J., M. R. Swerdel, B. Blue, J. N. Clark, and D. P. Bonner. 1991. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831-835.
18. Olsen, S. J., M. R. Swerdel, B. Blue, S. Williams, and J. M. Clark. 1990. Localized Candida infections in mice treated with amphotericin B lipid complex (ABLC) and putative mode of ABLC transport, abstr. A-111, p. 19. In Abstracts of the 90th General Meeting of the American Society for Microbiology 1990. American Society for Microbiology, Washington, D.C.
19. Pandey, R. C., V. F. German, Y. Nishikawa, and K. L. Rinehart. 1971. Polyene antibiotics II: the structure of tetrin A. J. Am. Chem. Soc. 93:3738-3747.
20. Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J. Antimicrob. Chemother. 33:73-81.
21. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternack, and A. S. Janoff. 1992. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
22. Walsh, T. J., J. W. Hiemenz, N. Siebel, and E. J. Anaissie. 1994. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis, abstr. M69, p. 247. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Wasan, K., and G. Lopez-Berestein. 1994. Modification of amphotericin B's therapeutic index by increasing its association with high-density lipoproteins. Ann. N.Y. Acad. Sci. 730:93-106.
24. Wasan, K. M., G. A. Brazeau, A. Keyhani, A. C. Hayman, and G. Lopez-Berestein. 1993. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246-250.
25. Wong, S. L. 1992. High performance liquid chromatographic assay for the quantitation of total amphotericin B with internal standard in human blood. Internal report. The Liposome Company, Inc., Princeton, N.J.